Literature DB >> 27344070

Characterization of Substance P processing in mouse spinal cord S9 fractions using high-resolution Quadrupole-Orbitrap mass spectrometry.

Mouna Saidi1, Soufiane Kamali1, Francis Beaudry2.   

Abstract

Tachykinins are a family of pronociceptive neuropeptides with a specific role in pain and inflammation. Several mechanisms regulate endogenous tachykinins and Substance P (SP) levels, including the differential expression of protachykinin mRNA and the controlled secretion of tachykinins from neurons. Proteolysis is suspected to regulate extracellular SP concentrations but few studies were conducted on the metabolism of proneuropeptides and neuropeptides. Here, we provide evidence that proteolysis controls SP levels in the spinal cord leading to the formation of active C-terminal fragments. Using high-resolution mass spectrometry, specific tachykinins fragments were characterized and quantified. The metabolic stability of β-Tachykinin58-71 and SP were very short resulting in half-life of 5.7 and 3.5min respectively. Several C-terminal fragments were identified, including SP3-11, SP5-11 and SP8-11, which conserve affinity for the Neurokinin 1 receptor. Interestingly, the metabolic stability of C-terminal fragments was significantly superior. Two specific Prolyl endopeptidase inhibitors were used and showed a significant reduction in the rate of formation of SP3-11 and SP5-11 providing strong evidence that Prolyl endopeptidase is involved into N-terminal processing of SP in the spinal cord.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mass spectrometry; Pain; Prolyl endopeptidase (PREP); Proteolysis; S9 fractions; SP(3–11); SP(5–11); Spinal cords; Substance P; Tachykinin; β-Tachykinin(58–71)

Mesh:

Substances:

Year:  2016        PMID: 27344070     DOI: 10.1016/j.npep.2016.06.002

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  4 in total

Review 1.  Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics.

Authors:  Krishna D B Anapindi; Elena V Romanova; James W Checco; Jonathan V Sweedler
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

2.  Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?

Authors:  Pekka T Männistö; J Arturo García-Horsman
Journal:  Front Aging Neurosci       Date:  2017-02-14       Impact factor: 5.750

3.  A Chitosan-Based Liposome Formulation Enhances the In Vitro Wound Healing Efficacy of Substance P Neuropeptide.

Authors:  Tamara Mengoni; Manuela Adrian; Susana Pereira; Beatriz Santos-Carballal; Mathias Kaiser; Francisco M Goycoolea
Journal:  Pharmaceutics       Date:  2017-12-06       Impact factor: 6.321

Review 4.  The Regenerative Potential of Substance P.

Authors:  Patrycja Redkiewicz
Journal:  Int J Mol Sci       Date:  2022-01-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.